Relapsed Neuroblastoma Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Relapsed Neuroblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Relapsed Neuroblastoma
University of Birmingham160 enrolled23 locationsNCT07334301
Recruiting
Phase 1

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma
Stephan Grupp MD PhD38 enrolled1 locationNCT07007117
Recruiting
Phase 1Phase 2

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma
Roberto Chiarle42 enrolled2 locationsNCT06803875
Recruiting
Phase 1

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

High Risk NeuroblastomaRetinoblastomaRefractory Neuroblastoma+2 more
Stephan Grupp MD PhD45 enrolled1 locationNCT05650749
Recruiting
Phase 1

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NeuroblastomaRefractory OsteosarcomaRefractory Neuroblastoma+2 more
Emory University24 enrolled1 locationNCT05400603
Recruiting
Phase 1

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Steven DuBois, MD18 enrolled2 locationsNCT07027748
Recruiting
Phase 1Phase 2

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Refractory NeuroblastomaRelapsed Neuroblastoma
Nationwide Children's Hospital31 enrolled1 locationNCT04211675
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled1 locationNCT06721689